Breaking News Instant updates and real-time market news.

CAH

Cardinal Health

$50.76

0.36 (0.71%)

, MRK

Merck

$81.30

-3.24 (-3.83%)

08:12
10/23/19
10/23
08:12
10/23/19
08:12

FDA News to hold a summit

14th Annual FDA Inspections Summit to be held in Bethesda, MD on October 23-25 with presentations to begin on October 23 at 1 pm. Webcast Link

CAH

Cardinal Health

$50.76

0.36 (0.71%)

MRK

Merck

$81.30

-3.24 (-3.83%)

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

CAH Cardinal Health
$50.76

0.36 (0.71%)

09/11/19
DBAB
09/11/19
INITIATION
Target $50
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated Cardinal Health with a Hold rating and a price target of $50 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, recent large customer repricings, and opioid litigation.
10/16/19
LEHM
10/16/19
NO CHANGE
Target $156
LEHM
Equal Weight
Barclays ups McKesson target on probability of favorable settlement
If the $18B drug distributor opioid settlement, as reported last night by the Wall Street Journal, covers nearly all outstanding cases, and does not include any accelerated upfront payments for the industry, then it would likely be viewed net positive by investors and could lead to multiple expansion from current share levels, Barclays analyst Steve Valiquette tells investors in a research note. The analyst believes the possibility of a settlement is greater over the next week ahead of the start of the Ohio multi-district litigation. To reflect a higher probability of a favorable settlement, Valiquette raised his price target for McKesson (MCK) to $156 from $144 while keeping an Equal Weight rating on the shares.
10/16/19
JEFF
10/16/19
NO CHANGE
JEFF
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
Reports that the drug distributors, AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) have proposed an $18B settlement payable over 18 years to broadly settle outstanding lawsuits resulting from the companies' distribution of opioids should eliminate a longstanding overhang on the group, if finalized, Jefferies analyst Brian Tanquilut tells investors in a research note. With investors generally expecting a settlement of $15B-$25B, payable over a five-to-ten year time frame, the reported settlement proposal should be viewed as a positive, says the analyst. Tanquilut says the $18B payable over 18 years would be better than investors' current expectations. As sector fundamentals are improving, "elimination of long-standing overhang should make the group ownable again," he contends. The analyst prefers Buy-rated McKesson over Hold-rated AmerisourceBergen and Cardinal Health.
10/16/19
JEFF
10/16/19
NO CHANGE
JEFF
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
Reports that the drug distributors, AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) have proposed an $18B settlement payable over 18 years to broadly settle outstanding lawsuits resulting from the companies' distribution of opioids should eliminate a longstanding overhang on the group, if finalized, Jefferies analyst Brian Tanquilut tells investors in a research note. With investors generally expecting a settlement of $15B-$25B, payable over a five-to-ten year time frame, the reported settlement proposal should be viewed as a positive, says the analyst. Tanquilut says the $18B payable over 18 years would be better than investors' current expectations. As sector fundamentals are improving, "elimination of long-standing overhang should make the group ownable again," he contends. The analyst prefers Buy-rated McKesson over Hold-rated AmerisourceBergen and Cardinal Health.
MRK Merck
$81.30

-3.24 (-3.83%)

10/10/19
JPMS
10/10/19
NO CHANGE
Target $96
JPMS
Overweight
JPMorgan analysis indicates 'highly inexpensive valuation' for Merck
Investor sentiment on Merck shares remains positive but relative valuation and Keytruda concentration remains the primary pushback on the thesis, JPMorgan analyst Chris Schott tells investors in a research note. However, the analyst's sum-of-the-parts valuation analysis indicates a "highly inexpensive valuation" when incorporating a premium for the company's Animal health and Vaccines franchises. Further, while Keytruda represents a sizable portion of Merck's earnings and growth, the company has a full decade to further develop its pipeline and next-generation product offerings before the product faces biosimilar competition, Schott contends. As such, he continues to see Merck as one of the best positioned names in his coverage group. The analyst keeps an Overweight rating on the shares with a $96 price target.
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Neutral
Merck reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Merck with a Neutral rating and $90 price target. The analyst said he has a conservative near-term outlook on Merck as he sees "limited higher-impact events driving further positive sentiment."
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.

TODAY'S FREE FLY STORIES

SPWR

SunPower

$8.29

0.3 (3.75%)

07:10
11/18/19
11/18
07:10
11/18/19
07:10
Syndicate
SunPower files to sell 22M shares of common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.66

-0.0885 (-11.80%)

07:09
11/18/19
11/18
07:09
11/18/19
07:09
Recommendations
Jaguar Health analyst commentary  »

Jaguar Health price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$209.97

4.96 (2.42%)

, MTEM

Molecular Templates

$7.23

0.22 (3.14%)

07:08
11/18/19
11/18
07:08
11/18/19
07:08
Hot Stocks
Vertex, Molecular Templates collaborate for targeted conditionining regimens »

Vertex Pharmaceuticals…

VRTX

Vertex

$209.97

4.96 (2.42%)

MTEM

Molecular Templates

$7.23

0.22 (3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

ADUS

Addus HomeCare

$84.27

0.13 (0.15%)

07:08
11/18/19
11/18
07:08
11/18/19
07:08
Hot Stocks
Addus HomeCare provides update on operations in Illinois markets »

Addus HomeCare provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROK

Rockwell Automation

$200.22

1.32 (0.66%)

07:07
11/18/19
11/18
07:07
11/18/19
07:07
Conference/Events
Rockwell Automation to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

SEEL

Seelos Therapeutics

$0.86

0.0702 (8.84%)

07:07
11/18/19
11/18
07:07
11/18/19
07:07
Recommendations
Seelos Therapeutics analyst commentary  »

Seelos Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORTX

Orchard Therapeutics

$10.39

-0.3 (-2.81%)

07:06
11/18/19
11/18
07:06
11/18/19
07:06
Hot Stocks
Orchard Therapeutics granted EMA accelerated assessment for OTL-200 »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MYSZ

MySize

$0.36

-0.015 (-4.00%)

07:05
11/18/19
11/18
07:05
11/18/19
07:05
Hot Stocks
MySize announces one-for-fifteen reverse stock split »

My Size announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDI

Standard Diversified

$10.89

-0.21 (-1.89%)

, TPB

Turning Point Brands

$26.59

0.15 (0.57%)

07:05
11/18/19
11/18
07:05
11/18/19
07:05
Hot Stocks
Standard Diversified intends to pursue merger with Turning Point Brands »

Standard Diversified…

SDI

Standard Diversified

$10.89

-0.21 (-1.89%)

TPB

Turning Point Brands

$26.59

0.15 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
11/18/19
11/18
07:05
11/18/19
07:05
General news
FX Update: The pound has rallied quite sharply »

FX Update: The pound has…

07:05
11/18/19
11/18
07:05
11/18/19
07:05
General news
European stock markets are mostly lower »

European stock markets…

TWTR

Twitter

$29.25

0.36 (1.25%)

07:05
11/18/19
11/18
07:05
11/18/19
07:05
Recommendations
Twitter analyst commentary  »

Twitter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

GPOR

Gulfport Energy

$3.10

(0.00%)

07:04
11/18/19
11/18
07:04
11/18/19
07:04
Hot Stocks
Gulfport Energy says chairman David Houston will not seek re-election »

The Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$3.10

(0.00%)

07:03
11/18/19
11/18
07:03
11/18/19
07:03
Hot Stocks
Gulfport Energy suspends share repurchase program, completes headcount reduction »

Gulfport Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAD

Lithia Motors

$160.67

-0.19 (-0.12%)

07:03
11/18/19
11/18
07:03
11/18/19
07:03
Hot Stocks
Lithia Motors promotes Chris Holzshu to COO »

Lithia Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$21.00

1.04 (5.21%)

07:03
11/18/19
11/18
07:03
11/18/19
07:03
Hot Stocks
Alkermes to acquire Rodin Therapeutics »

Alkermes and Rodin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$165.93

1.17 (0.71%)

07:03
11/18/19
11/18
07:03
11/18/19
07:03
Downgrade
Workday rating change  »

Morgan Stanley cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

07:02
11/18/19
11/18
07:02
11/18/19
07:02
Conference/Events
Salesforce to host investor day at Dreamforce 2019 »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

ALKS

Alkermes

$21.00

1.04 (5.21%)

07:01
11/18/19
11/18
07:01
11/18/19
07:01
Hot Stocks
Breaking Hot Stocks news story on Alkermes »

Alkermes to acquire Rodin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCN

Anchiano Therapeutics

$1.93

-0.32 (-14.22%)

06:58
11/18/19
11/18
06:58
11/18/19
06:58
Downgrade
Anchiano Therapeutics rating change  »

Anchiano Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLX

Protalix

$0.20

(0.00%)

06:57
11/18/19
11/18
06:57
11/18/19
06:57
Hot Stocks
Protalix, Chiesi announce results from pre-BLA meeting with FDA for PRX-102 »

Protalix, and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$0.68

0.0405 (6.33%)

06:57
11/18/19
11/18
06:57
11/18/19
06:57
Hot Stocks
McDermott awarded 'sizeable' technology, EBE contracts »

McDermott announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$90.35

0.03 (0.03%)

06:57
11/18/19
11/18
06:57
11/18/19
06:57
Hot Stocks
Tyson beef plant in Kansas to resume operations in December »

Following the August 9…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$8.32

0.14 (1.71%)

06:56
11/18/19
11/18
06:56
11/18/19
06:56
Conference/Events
Overstock.com to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TRIP

TripAdvisor

$31.15

0.15 (0.48%)

06:55
11/18/19
11/18
06:55
11/18/19
06:55
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 25

    Nov

  • 26

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.